Jun Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun Kang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Limin Rong
Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
3 shared publications Bin Liu
Department of Spine Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
2 shared publicationsMao Pang
Department of Spine Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
2 shared publications- Senyu Yao
Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications Songfu Zou
Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publicationsXu Huang
Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Clinical trial landscape of cell therapy for spinal cord injury: from integrated practices to future developments
Introduction: Spinal cord injury (SCI) precipitates a multiphasic secondary injury cascade that establishes a hostile, inhibitory microenvironment, rendering the condition refractory to conventional surgical stabilization and rehabilitation. While cell-based therapies offer promise for neural reconstruction, their clinical translation is impeded by protocol heterogeneity and fragmented safety data. To address this, we mapped clinical trials for SCI to quantify patient demographic parameters, identify lineage-specific adverse-event patterns, evaluate objective motor and sensory efficacy outcomes, and analyze methodological trial designs to formulate concrete structural recommendations for future advanced-phase trials. Methods: We analyzed clinical trials from the Web of Science Core Collection (SCIE and ESCI) published since 2005. The dataset comprised 116 eligible studies involving patients with SCI receiving cellular therapies with reported safety outcomes. We employed a dual-method approach combining manual extraction of clinical characteristics (demographics, interventions, adverse events, efficacy outcomes) with quantitative data analysis. Statistical associations between therapeutic variables (cell type, route, dosage) and safety profiles were evaluated using Fisher’s exact test. Results: The clinical landscape is predominantly defined by early-phase (Phase 1: 59.5%), single-arm investigations (63.8%) utilizing autologous bone marrow-derived cells. Reflecting a cautious paradigm to minimize severe complications, patient selection frequently targeted the hemodynamically stable chronic phase (58.3%) and thoracic SCI (21.6%). Safety analyses revealed lineage-specific profiles: mesenchymal stromal cells were significantly associated with transient fever ( P = 0.038), whereas intrathecal administration correlated with procedural symptoms such as headache ( P < 0.001). The observation of higher systemic adverse event rates in low-dose cohorts was likely confounded by the mandatory concurrent immunosuppressive regimens required for specific allogeneic lineages, rather than the absolute cell dose. Regarding therapeutic efficacy, outcomes were critically influenced by the chronological phase of injury. Patients treated in the acute or subacute phases exhibited higher rates of neurological improvement, though distinguishing this from spontaneous recovery remains challenging, whereas chronic phase interventions demonstrated more limited primary sensorimotor gains. Additionally, intrathecal administration showed an advantage in preserving sensory pathways due to minimized structural disruption, while dose requirements could not be generalized and varied fundamentally based on specific cellular mechanisms of action. Discussion: While the baseline safety of cellular transplantation for spinal cord injury is established, clinical translation remains hindered by methodological heterogeneity, imprecise patient stratification, and a reliance on single-arm trial designs. To navigate this translational bottleneck, future investigations should adopt multi-tiered methodological frameworks. First, study designs should transition toward controlled protocols, utilizing crossover designs for chronic cohorts and matched historical or synthetic controls for acute and subacute phases. Concurrently, patient selection must evolve from broad clinical grading to advanced stratification. Integrating biomarkers, electrophysiology, and imaging to objectively quantify tissue sparing can better identify responsive subgroups, thereby improving trial efficiency and accelerating clinical translation. Beyond cohort refinement, intervention parameters, specifically dosage and delivery routes, should be individualized according to cell lineage, as adverse events associate more with intrinsic cellular biology and procedural invasiveness. Furthermore, isolating the true therapeutic effect requires the standardization and reporting of confounding variables, such as immunosuppressive regimens and physical rehabilitation. Finally, by separating shorter-term efficacy measurements from long-term safety registries, the field can facilitate a more reliable and objective clinical translation.
- 20 July 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Open AccessClinical trial landscape of cell therapy for spinal cord injury: from integrated practices to future developments
Introduction: Spinal cord injury (SCI) precipitates a multiphasic secondary injury cascade that establishes a hostile, inhibitory microenvironment, rendering the condition refractory to conventional surgical stabilization and rehabilitation. While cell-based therapies offer promise for neural reconstruction, their clinical translation is impeded by protocol heterogeneity and fragmented safety data. To address this, we mapped clinical trials for SCI to quantify patient demographic parameters, identify lineage-specific adverse-event patterns, evaluate objective motor and sensory efficacy outcomes, and analyze methodological trial designs to formulate concrete structural recommendations for future advanced-phase trials. Methods: We analyzed clinical trials from the Web of Science Core Collection (SCIE and ESCI) published since 2005. The dataset comprised 116 eligible studies involving patients with SCI receiving cellular therapies with reported safety outcomes. We employed a dual-method approach combining manual extraction of clinical characteristics (demographics, interventions, adverse events, efficacy outcomes) with quantitative data analysis. Statistical associations between therapeutic variables (cell type, route, dosage) and safety profiles were evaluated using Fisher’s exact test. Results: The clinical landscape is predominantly defined by early-phase (Phase 1: 59.5%), single-arm investigations (63.8%) utilizing autologous bone marrow-derived cells. Reflecting a cautious paradigm to minimize severe complications, patient selection frequently targeted the hemodynamically stable chronic phase (58.3%) and thoracic SCI (21.6%). Safety analyses revealed lineage-specific profiles: mesenchymal stromal cells were significantly associated with transient fever ( P = 0.038), whereas intrathecal administration correlated with procedural symptoms such as headache ( P < 0.001). The observation of higher systemic adverse event rates in low-dose cohorts was likely confounded by the mandatory concurrent immunosuppressive regimens required for specific allogeneic lineages, rather than the absolute cell dose. Regarding therapeutic efficacy, outcomes were critically influenced by the chronological phase of injury. Patients treated in the acute or subacute phases exhibited higher rates of neurological improvement, though distinguishing this from spontaneous recovery remains challenging, whereas chronic phase interventions demonstrated more limited primary sensorimotor gains. Additionally, intrathecal administration showed an advantage in preserving sensory pathways due to minimized structural disruption, while dose requirements could not be generalized and varied fundamentally based on specific cellular mechanisms of action. Discussion: While the baseline safety of cellular transplantation for spinal cord injury is established, clinical translation remains hindered by methodological heterogeneity, imprecise patient stratification, and a reliance on single-arm trial designs. To navigate this translational bottleneck, future investigations should adopt multi-tiered methodological frameworks. First, study designs should transition toward controlled protocols, utilizing crossover designs for chronic cohorts and matched historical or synthetic controls for acute and subacute phases. Concurrently, patient selection must evolve from broad clinical grading to advanced stratification. Integrating biomarkers, electrophysiology, and imaging to objectively quantify tissue sparing can better identify responsive subgroups, thereby improving trial efficiency and accelerating clinical translation. Beyond cohort refinement, intervention parameters, specifically dosage and delivery routes, should be individualized according to cell lineage, as adverse events associate more with intrinsic cellular biology and procedural invasiveness. Furthermore, isolating the true therapeutic effect requires the standardization and reporting of confounding variables, such as immunosuppressive regimens and physical rehabilitation. Finally, by separating shorter-term efficacy measurements from long-term safety registries, the field can facilitate a more reliable and objective clinical translation.
- Open Access
Safety and early efficacy of iPSC-derived motor neuron progenitor cells in subacute spinal cord injury: protocol for a phase I, multicentre, open-label, single-arm trial
Introduction: Spinal cord injury (SCI) frequently results in severe neurological impairment due to neural tissue destruction and scarring, representing a substantial and increasing global health burden. Current standard treatments primarily focus on preventing secondary complications but offer limited efficacy in repairing neural circuits or reversing neurological deficits. Stem cell transplantation, particularly using induced pluripotent stem cell (iPSC)-derived therapies, presents a regenerative strategy that avoids the ethical constraints associated with embryonic stem cells while providing a scalable source for cellular therapeutics. Specifically, allogeneic, ‘off-the-shelf’ iPSC-derived motor neuron progenitors offer a standardised and scalable approach, supported by a dual therapeutic mechanism observed in preclinical models. Methods and analysis: This is a prospective, multicentre, open-label, single-arm clinical study involving 12–24 adult patients with subacute SCI. To evaluate safety and tolerability, the trial is structured into sequential Single Ascending Dose (SAD; n=6–12) and Multiple Ascending Dose (MAD; n=6–12) phases. Both phases employ a standard ‘3+3’ dose-escalation design across two dose levels (level 1: 5×10⁷ cells/dose; level 2: 1.5×10⁸ cells/dose). Participants in the SAD phase receive a single intrathecal administration, whereas those in the MAD phase receive four biweekly intrathecal administrations. Dose escalation, cohort expansion and progression from the SAD to the MAD phase are strictly contingent on the absence of dose-limiting toxicities (DLTs) over a 28-day observation window following the single dose (SAD) or the final dose (MAD). The primary endpoint is to determine the incidence of treatment-related adverse events (AEs) and serious AEs, identify DLTs and establish the maximum tolerated dose as well as the recommended phase II dose. Efficacy will be assessed by evaluating longitudinal changes in American Spinal Injury Association (ASIA) Impairment Scale grade, American Spinal Injury Association (ASIA) sensory/motor scores and Spinal Cord Independence Measure score at predefined follow-up visits (days 29, 71, 90, 180, 270 and 360) up to 360 days post-baseline. Exploratory objectives include characterising the potential therapeutic mechanisms and broader clinical impact through longitudinal assessment of cerebrospinal fluid biomarkers, neurophysiological function, bladder outcomes and spinal cord imaging metrics. Ethics and dissemination: The study protocol has received ethical approval from the Institutional Ethics Committees of the Third Affiliated Hospital of Sun Yat-sen University (Approval No. YW2025-012-01) and the Third Hospital of Hebei Medical University (Approval No. 2025–071-2). Furthermore, the investigational product has secured regulatory clearance for clinical trials from both the China National Medical Products Administration (Clinical Trial Notification No. 2025LP01101) and the US Food and Drug Administration (IND No. 31234). Written informed consent will be obtained from all participants before participation. Moreover, strict adherence will be maintained to the Declaration of Helsinki and Good Clinical Practice guidelines throughout the study. To ensure transparency and broad dissemination, the study results will be disseminated through peer-reviewed publications and conference presentations. Trial registration number: NCT06976229 .
Open AccessSafety and early efficacy of iPSC-derived motor neuron progenitor cells in subacute spinal cord injury: protocol for a phase I, multicentre, open-label, single-arm trial
Introduction: Spinal cord injury (SCI) frequently results in severe neurological impairment due to neural tissue destruction and scarring, representing a substantial and increasing global health burden. Current standard treatments primarily focus on preventing secondary complications but offer limited efficacy in repairing neural circuits or reversing neurological deficits. Stem cell transplantation, particularly using induced pluripotent stem cell (iPSC)-derived therapies, presents a regenerative strategy that avoids the ethical constraints associated with embryonic stem cells while providing a scalable source for cellular therapeutics. Specifically, allogeneic, ‘off-the-shelf’ iPSC-derived motor neuron progenitors offer a standardised and scalable approach, supported by a dual therapeutic mechanism observed in preclinical models. Methods and analysis: This is a prospective, multicentre, open-label, single-arm clinical study involving 12–24 adult patients with subacute SCI. To evaluate safety and tolerability, the trial is structured into sequential Single Ascending Dose (SAD; n=6–12) and Multiple Ascending Dose (MAD; n=6–12) phases. Both phases employ a standard ‘3+3’ dose-escalation design across two dose levels (level 1: 5×10⁷ cells/dose; level 2: 1.5×10⁸ cells/dose). Participants in the SAD phase receive a single intrathecal administration, whereas those in the MAD phase receive four biweekly intrathecal administrations. Dose escalation, cohort expansion and progression from the SAD to the MAD phase are strictly contingent on the absence of dose-limiting toxicities (DLTs) over a 28-day observation window following the single dose (SAD) or the final dose (MAD). The primary endpoint is to determine the incidence of treatment-related adverse events (AEs) and serious AEs, identify DLTs and establish the maximum tolerated dose as well as the recommended phase II dose. Efficacy will be assessed by evaluating longitudinal changes in American Spinal Injury Association (ASIA) Impairment Scale grade, American Spinal Injury Association (ASIA) sensory/motor scores and Spinal Cord Independence Measure score at predefined follow-up visits (days 29, 71, 90, 180, 270 and 360) up to 360 days post-baseline. Exploratory objectives include characterising the potential therapeutic mechanisms and broader clinical impact through longitudinal assessment of cerebrospinal fluid biomarkers, neurophysiological function, bladder outcomes and spinal cord imaging metrics. Ethics and dissemination: The study protocol has received ethical approval from the Institutional Ethics Committees of the Third Affiliated Hospital of Sun Yat-sen University (Approval No. YW2025-012-01) and the Third Hospital of Hebei Medical University (Approval No. 2025–071-2). Furthermore, the investigational product has secured regulatory clearance for clinical trials from both the China National Medical Products Administration (Clinical Trial Notification No. 2025LP01101) and the US Food and Drug Administration (IND No. 31234). Written informed consent will be obtained from all participants before participation. Moreover, strict adherence will be maintained to the Declaration of Helsinki and Good Clinical Practice guidelines throughout the study. To ensure transparency and broad dissemination, the study results will be disseminated through peer-reviewed publications and conference presentations. Trial registration number: NCT06976229 .
- Open Access
- 13 May 2026
- Published by Elsevier in SSRN Electronic Journal
Neuro-structural Biomarkers in Serum and CSF for Severity Grading and Prognosis in Spinal Cord Injury: A Systematic Review and Network Meta-Analysis
Background: Clinical evaluation of spinal cord injury relies on assessments that are frequently limited in the acute phase. Objective fluid biomarkers are needed to complement standard evaluations for patient stratification, but their relative performance and the comparative utility of serum versus cerebrospinal fluid remain uncertain. We aimed to evaluate the relative performance of seven neuro-structural biomarkers across diagnostic, severity, and prognostic domains, and to compare the utility of serum and cerebrospinal fluid profiling.Methods: We did a systematic review and network meta-analysis. We searched PubMed, Web of Science, Scopus, and the Cochrane Library from database inception to Jan 7, 2026, for randomized clinical trials and observational studies. Eligible studies quantified targeted neuro-structural biomarkers (NSE, UCH-L1, NF-L, NF-H, Tau, GFAP, and S100B) in serum or cerebrospinal fluid within 4 days of traumatic spinal cord injury in patients aged 16 years or older. Two investigators independently extracted data. We used a frequentist network meta-analysis to calculate standardized mean differences (SMDs) and surface under the cumulative ranking (SUCRA) scores for diagnostic discrimination (spinal cord injury versus controls), severity stratification (American Spinal Injury Association Impairment Scale grade), and prognostic prediction of functional recovery. This study is registered with PROSPERO (CRD420261285447).Results: A total of 33 studies comprising 1489 participants were included. For diagnostic discrimination, serum NSE achieved the highest ranking (SUCRA 66.2%), and indirect comparisons showed no significant difference in diagnostic capacity between serum and CSF profiling (SMD -0.58, 95% CI -2.93 to 1.77). For severity stratification, GFAP demonstrated consistent statistical significance across both biological matrices, differentiating complete from incomplete injuries (serum SMD 1.97, 95% CI 0.98 to 2.95) and motor-complete from motor-incomplete injuries (serum SMD 1.61, 95% CI 1.00 to 2.21). For prognostic prediction, serum NF-L emerged as a prominent indicator (SUCRA 77.1%), demonstrating predictive utility with no significant difference from CSF NF-L (SMD -1.39, 95% CI, -3.47 to 0.69). Kinetic analysis indicated that while GFAP concentrations peak within the first 24 hours post-injury, NSE and NF-L exhibit progressive accumulation or sustained elevation over subsequent days.Interpretation: Fluid biomarkers offer distinct contextual utilities in acute spinal cord injury. NSE provides an early objective indication of neural damage in assessment vacuums, GFAP demonstrates consistent reliability for severity stratification, and NF-L offers substantial value for prognostic prediction and potential pharmacodynamic monitoring. Serum profiling shows potential comparable to cerebrospinal fluid, supporting its evaluation as a less invasive tool for sequential monitoring. Large-scale prospective investigations utilizing harmonized analytical platforms are required to empirically validate these findings.
- 13 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNeuro-structural Biomarkers in Serum and CSF for Severity Grading and Prognosis in Spinal Cord Injury: A Systematic Review and Network Meta-Analysis
Background: Clinical evaluation of spinal cord injury relies on assessments that are frequently limited in the acute phase. Objective fluid biomarkers are needed to complement standard evaluations for patient stratification, but their relative performance and the comparative utility of serum versus cerebrospinal fluid remain uncertain. We aimed to evaluate the relative performance of seven neuro-structural biomarkers across diagnostic, severity, and prognostic domains, and to compare the utility of serum and cerebrospinal fluid profiling.Methods: We did a systematic review and network meta-analysis. We searched PubMed, Web of Science, Scopus, and the Cochrane Library from database inception to Jan 7, 2026, for randomized clinical trials and observational studies. Eligible studies quantified targeted neuro-structural biomarkers (NSE, UCH-L1, NF-L, NF-H, Tau, GFAP, and S100B) in serum or cerebrospinal fluid within 4 days of traumatic spinal cord injury in patients aged 16 years or older. Two investigators independently extracted data. We used a frequentist network meta-analysis to calculate standardized mean differences (SMDs) and surface under the cumulative ranking (SUCRA) scores for diagnostic discrimination (spinal cord injury versus controls), severity stratification (American Spinal Injury Association Impairment Scale grade), and prognostic prediction of functional recovery. This study is registered with PROSPERO (CRD420261285447).Results: A total of 33 studies comprising 1489 participants were included. For diagnostic discrimination, serum NSE achieved the highest ranking (SUCRA 66.2%), and indirect comparisons showed no significant difference in diagnostic capacity between serum and CSF profiling (SMD -0.58, 95% CI -2.93 to 1.77). For severity stratification, GFAP demonstrated consistent statistical significance across both biological matrices, differentiating complete from incomplete injuries (serum SMD 1.97, 95% CI 0.98 to 2.95) and motor-complete from motor-incomplete injuries (serum SMD 1.61, 95% CI 1.00 to 2.21). For prognostic prediction, serum NF-L emerged as a prominent indicator (SUCRA 77.1%), demonstrating predictive utility with no significant difference from CSF NF-L (SMD -1.39, 95% CI, -3.47 to 0.69). Kinetic analysis indicated that while GFAP concentrations peak within the first 24 hours post-injury, NSE and NF-L exhibit progressive accumulation or sustained elevation over subsequent days.Interpretation: Fluid biomarkers offer distinct contextual utilities in acute spinal cord injury. NSE provides an early objective indication of neural damage in assessment vacuums, GFAP demonstrates consistent reliability for severity stratification, and NF-L offers substantial value for prognostic prediction and potential pharmacodynamic monitoring. Serum profiling shows potential comparable to cerebrospinal fluid, supporting its evaluation as a less invasive tool for sequential monitoring. Large-scale prospective investigations utilizing harmonized analytical platforms are required to empirically validate these findings.
- Open Access
- 11 September 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (12) , 2599-2610
Ischemia-free liver transplantation as a novel approach to improve survival and clinical outcomes in the acute-on-chronic liver failure scenario
- 11 September 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (12) , 2599-2610
Open AccessIschemia-free liver transplantation as a novel approach to improve survival and clinical outcomes in the acute-on-chronic liver failure scenario